Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-5127 in Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537Phase 1Recruiting
- Sponsor
- Revolution Medicines
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RMC-5127 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more, sponsored by Revolution Medicines. Primary endpoints: Number of patients with adverse events at 3 years, Changes in vital signs at 3 years and 3 more. Started Jan 2026; status: recruiting.
02
Drugs
RMC-5127
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07349537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349537.